Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for many hematologic malignancies or hematopoietic dysfunction syndromes in adult patients, but the application is still limited due to major complications, such as severe graft versus host disease (GvHD) and/or infectious complications. Diagnosis of aGvHD is based on clinical features and biopsies, a non invasive, unbiased laboratory test was developed earlier and has been evaluated prospectively and blinded on more than 1290 samples collected from more than 327 patients undergoing allo-HSCT at Hannover Medical School (MHH) and 7 additional clinics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
